title: A single histrelin implant is effective for 2 years for treatment of central precocious puberty.
abstract: We investigated whether a "yearly" histrelin implant would provide pubertal suppression when left in place for 2 years. Equivalent suppression was observed when comparing 12 and 24 months in 33 children with central precocious puberty. A single implant for 2 years reduces cost and number of implant procedures.
authors.affiliation: Department of Pediatrics, Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, IN.
authors.forename: Katherine A
authors.initials: KA
authors.lastname: Lewis
authors.forename: Andrea K
authors.initials: AK
authors.lastname: Goldyn
authors.forename: Karen W
authors.initials: KW
authors.lastname: West
authors.forename: Erica A
authors.initials: EA
authors.lastname: Eugster
mesh_terms: D002648:Child; D002675:Child, Preschool; D004343:Drug Implants; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D011629:Puberty, Precocious / Q000188:drug therapy*; D012737:Sex Factors; D013997:Time Factors
chemical_list: D004343:Drug Implants; D007987:Gonadotropin-Releasing Hormone; D007986:Luteinizing Hormone; C029256:histrelin
keywords: CPP; Central precocious puberty; GnRHa; Gonadotropin releasing hormone analog; HPG; Hypothalamic-pituitary-gonadal; LH; Luteinizing hormone; US; Ultrasensitive